Archives
-
KG-501 Workflows for CREB–KIX Assays in Cancer Models
2026-09-25
Use KG-501 to test whether CREB–coactivator signaling contributes to transcriptional and macrophage responses—not as a stand-in for a TLR4-specific inhibitor. This workflow pairs dose and viability controls with the macrophage readouts used in colitis-associated colorectal cancer research.
-
HyperScribe™ K1066: mRNA Design for Disc Research
2026-09-24
Explore how HyperScribe™ All in One mRNA Synthesis Kit II (K1066) can support controlled mRNA experiments inspired by emerging intervertebral disc research. We connect kit components to a preclinical fibroblast strategy while distinguishing practical workflow considerations from findings the study has actually established.
-
Mildronate Lipidoids for Lower-Inflammation mRNA Vaccines
2026-09-24
The 2024 ACS Nano study reports mLNP-69, a lipid nanoparticle formulation using a low dose of mildronate-derived cationic lipid to deliver mRNA while reducing local inflammation relative to an SM102-based comparator. Its prophylactic and therapeutic B16OVA melanoma results support further preclinical evaluation, but do not establish clinical safety or broad effectiveness across mRNA formulations.
-
Reducing Pollen Interference in EEM Bioaerosol Detection
2026-09-23
Zhang and colleagues tested how pollen affects excitation–emission matrix fluorescence classification of hazardous bioaerosol-related samples and evaluated spectral transformations with a random forest classifier. Fast Fourier transform processing produced the strongest reported result, improving classification accuracy by 9.2% to 89.24%, while highlighting the need to account for natural biological backgrounds in rapid detection systems.
-
Wnt/NR2F2 Drives Platinum Resistance in Brain Metastasis
2026-09-23
The reference study identifies a Wnt/NR2F2/GPX4 axis that links high glutathione consumption to ferroptosis suppression and acquired platinum resistance in lung cancer-derived brain metastases. Its integrated metabolomic, proteomic, genetic, and biochemical analyses provide a mechanistic framework for studying therapy resistance, while also highlighting the need for caution when translating pathway findings into chemical activation workflows.
-
Fluorouracil Workflows for Solid Tumor Research
2026-09-22
Build reproducible Fluorouracil and 5-Fluorouracil assays around concentration-response data, mechanism-linked controls, and stability-aware handling. This guide connects cytotoxicity screening with resistance biology, including practical extensions for colon cancer research, breast cancer research, and renal carcinoma models.
-
HyperScribe™ mRNA Synthesis for CAR mRNA
2026-09-22
Explore how an mRNA synthesis kit can support CD19 CAR mRNA development, from cap and nucleotide design to functional assay planning. This article translates recent in vivo CAR-T findings into practical molecular quality and workflow decisions.
-
AptaBLE: Deep Learning for Aptamer Design
2026-09-21
AptaBLE combines pretrained protein and nucleic acid encoders with symmetric bidirectional cross-attention to predict aptamer–protein binding across variable-length sequences. The preprint also reports two de novo generation strategies that produced target-binding aptamers with reported dissociation constants as low as 31 nM, positioning sequence-based modeling as a complement to SELEX rather than a replacement for experimental validation.
-
FLOT1–FOSL2–EphA2 Signaling in Alzheimer’s Disease
2026-09-21
The reference study identifies a FLOT1–FOSL2–EphA2 regulatory axis that links microglial molecular control to p38/MAPK signaling, neuroinflammation, and cognitive impairment in APP/PS1 mice. Its combination of interaction, transcriptional, pathway-perturbation, histological, and behavioral assays provides a mechanistic framework for studying microglial polarization in Alzheimer’s disease.
-
JXY, TLR4, and M1 Polarization in CAC
2026-09-20
The reference study shows that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice while shifting macrophages toward an M1-like phenotype through TLR4-associated signaling. Its integrated in vivo, histological, molecular, and functional design supports immune-microenvironment modulation as a mechanism of action, while also highlighting the need for more specific pathway validation.
-
EZ Cap™ Reagent GG: p21 mRNA Evidence
2026-09-19
EZ Cap™ Reagent GG is identified as product SKU B8177, but the supplied record does not define its cap chemistry or performance specifications. The referenced 2026 FASEB Journal study supports intravesical p21 mRNA–loaded lipid nanoparticles as a localized bladder-cancer research strategy, not as validation of this reagent.
-
Tetramethylrhodamine ethyl ester perchlorate: TMRE Workflow
2026-09-18
Use Tetramethylrhodamine ethyl ester perchlorate (TMRE) to convert mitochondrial membrane-potential changes into live-cell imaging and flow-cytometry data. This workflow shows how to distinguish depolarization from ROS accumulation and connect mitochondrial injury to caspase-3, NDUFS1, and ERO1α mechanisms.
-
EZ Cap™ Reagent GG in p21 mRNA-LNP Design
2026-09-18
Discover how EZ Cap™ Reagent GG can be evaluated as an upstream variable in p21 mRNA-LNP development for localized bladder cancer therapy. This article connects 5′-cap quality with translation, innate immune control, formulation performance, and assay design.
-
Mildronate Lipidoids for Lower-Inflammation mRNA Delivery
2026-09-17
The 2024 ACS Nano study developed mildronate-derived cationic lipids for low-dose lipid nanoparticles that preserved effective mRNA delivery while reducing local inflammation relative to an SM102-based comparator. In prophylactic and therapeutic B16OVA melanoma models, the mLNP-69 formulation supported cancer vaccine delivery, tumor prevention, or delayed tumor progression.
-
Firefly Luciferase mRNA: Workflow & Optimization
2026-09-17
Firefly Luciferase mRNA (ARCA, 5-moUTP) provides a sensitive, transient readout for delivery, expression, viability, and imaging studies. This workflow-focused guide shows how to handle the transcript, design controls, evaluate freeze–thaw effects in lipid nanoparticles, and troubleshoot weak or variable bioluminescence.